Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Conditions

• Brain and Central Nervous System Tumors

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• irinotecan hydrochloride — DRUG
• temozolomide — DRUG
• adjuvant therapy — PROCEDURE
• radiation therapy — RADIATION

Study Details

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy, such as temozolomide and irinotecan, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well radiation therapy, temozolomide, and irinotecan work in treating patients with newly diagnosed glioblastoma multiforme.

Key Dates

Start date

Nov 30, 2004

Status verified

Jan 2014

Primary completion

Oct 31, 2006

Completion

Nov 30, 2013

Study Design

Enrollment

170 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: RT with chemotherapy + post-radiation chemotherapy
  Radiation therapy (RT) with concurrent chemotherapy + post-radiation chemotherapy

Primary Outcome Measure

Overall survival [ Time Frame: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 18 months. ]

Locations (118)

Find similar trials in Phoenix, AZ

Related Studies

• 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
  Recruiting · Barbara Ann Karmanos Cancer Institute · Detroit, Michigan
• Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
  PHASE1/PHASE2 · Recruiting · National Institute of Neurological Disorders and Stroke (NINDS) · Bethesda, Maryland